Entasis Therapeutics (ETTX) Short Interest Ratio & Short Volume

Short interest is the volume of Entasis Therapeutics shares that have been sold short but have not yet been covered or closed out. As of June 15th, investors have sold 72,400 shares of ETTX short. 0.50% of Entasis Therapeutics' shares are currently sold short. Learn More on Entasis Therapeutics' current short interest.

Companies that have a short interest as a percentage of float below 10% indicates positive investor sentiment and few short sellers. Stocks with a short interest percentage above 10% is considered high, suggesting some investors are pessimistic about the stock. Companies with a short interest percentage of 20% or more indicates widespread negative sentiment. 0.50% of Entasis Therapeutics' floating shares are currently sold short.

Entasis Therapeutics saw a decrease in short interest during the month of June. As of June 15th, there was short interest totaling 72,400 shares, a decrease of 3.3% from the previous total of 74,900 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment.

Entasis Therapeutics currently has issued a total of 47,852,000 shares. Some of Entasis Therapeutics' outstanding shares are available for trading, while others are subject to various restrictions. The public float, also referred to as floating shares or "the float", are shares that publicly owned, unrestricted and available to trade on the open market. Entasis Therapeutics currently has a public float of 14,440,000 shares.

0.50% of Entasis Therapeutics' shares are currently sold short. Here is how the short interest of companies in the sector of "medical" compare to Entasis Therapeutics: Cellectar Biosciences, Inc. (8.66%), PDS Biotechnology Co. (16.77%), Emergent BioSolutions Inc. (11.38%), IO Biotech, Inc. (0.16%), Cartesian Therapeutics, Inc. (5.31%), InterCure Ltd. (0.33%), Anixa Biosciences, Inc. (1.90%), Annovis Bio, Inc. (13.62%), Barinthus Biotherapeutics plc (0.03%), Oramed Pharmaceuticals Inc. (1.44%),

As of the most recent reporting period, the following stocks had the largest short interest positions: Charter Communications, Inc. ($3.58 billion), Occidental Petroleum Co. ($3.23 billion), Lucid Group, Inc. ($2.31 billion), Coinbase Global, Inc. ($1.73 billion), Snowflake Inc. ($1.71 billion), Chesapeake Energy Co. ($1.66 billion), Rivian Automotive, Inc. ($1.63 billion), Williams-Sonoma, Inc. ($1.51 billion), Lumen Technologies, Inc. ($1.40 billion), and Diamondback Energy, Inc. ($1.37 billion). View all of the most shorted stocks.

Short selling ETTX is an investing strategy that aims to generate trading profit from Entasis Therapeutics as its price is falling. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit.

A short squeeze for Entasis Therapeutics occurs when it has a large amount of short interest and its stock increases in price. This forces short sellers to cover their short interest positions by buying actual shares of ETTX, which in turn drives the price of the stock up even further.

Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including ETTX, twice per month. The most recent reporting period available is June, 15 2022.